Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Latuda

- PMLiVE

Takeda suspended as vice president of Japanese industry body

Mis-labelling also prompts JPMA to takes action against CMO Nihon Pharmaceutical

- PMLiVE

Vanda withdraws EU application for schizophrenia drug

CHMP had previously refused to back the approval of Fanaptum

- PMLiVE

Takeda files IBD drug vedolizumab in Europe

Potential safer alternative to TNF blockers like Remicade and Humira

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

- PMLiVE

Takeda-Affymax recall Omontys in US after deaths

Severe allergic reactions reported in kidney disease patients taking anaemia drug

- PMLiVE

EU approves Alexza’s antipsychotic Adasuve

Company plans to launch it in third quarter of 2013 in partnership with Grupo Ferrer

Product updates from Japan

New approvals and filings include drugs from Takeda, Otsuka, Chugai and Astellas

- PMLiVE

Takeda gets FDA approval for alogliptin franchise in diabetes

Comprises Nesina, Oseni and Kazano

- PMLiVE

Takeda launches new business in China

Will serve as hub for importing medicines from across the world

- PMLiVE

Early 2013 sees drug filings, launches and approvals in Japan

Includes medicines from Bayer, Takeda, Astellas and Eisai

- PMLiVE

Takeda ends obesity alliance with Amylin

Comes more than a year after development of lead product was pulled

- PMLiVE

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links